Close Menu

University of Pennsylvania School of Medicine scientists have developed a high-throughput functional cell-based screen using bioluminescence imaging to identify small molecules that modulate p53 transcriptional activity or p53-related proteins in cancer cells, and exhibit anti-cancer activity in human colon cancer xenografts.

The study underscores the importance of p53-related pathways and downstream molecules as potential drug targets, and could help establish bioluminescent cell-based assays as an effective way to screen modulators of such targets.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.